Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: A medical technology company developing non-invasive testing solutions, primarily the Intelligent Fingerprinting (IFP) Drug Screening System. The company operates globally with segments in the United Kingdom, APAC, Americas, and Rest of World.
Key Financial Metrics
| Metric | Q1 2026 (Ended Sept 30, 2025) | Q1 2025 (Ended Sept 30, 2024) |
|---|---|---|
| Revenue | $1,111,797 | $872,287 |
| Gross Profit | $518,291 | $346,801 |
| Gross Margin | 46.6% | 39.7% |
| Net Loss (Attributable to INBS) | $(2,983,006) | $(2,685,633) |
| Net Loss Per Share (Basic/Diluted) | $(0.35) | $(0.70) |
| Cash and Cash Equivalents | $1,660,105 | $3,989,431 (End of prior period) |
| Working Capital | $(577,705) Deficit | Filing text does not provide clear prior period value |
| Accumulated Deficit | $(65,516,071) | $(54,649,965) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 27.5% year-over-year to $1.11 million, driven by a 42.8% increase in cartridge sales (consumables) and expansion of the customer base to 492 active accounts.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 36.5% to $2.66 million due to increased marketing and promotion. Conversely, development and regulatory expenses decreased 48.7% to $486,169 due to the timing of research partner engagements.
- Impairment Charge: The company recorded a one-time impairment loss of $261,780 related to long-lived assets held for sale (construction in progress), which was not present in the prior year.
- Capital Structure: Significant equity activity occurred, including a warrant inducement transaction raising approximately $3.33 million net and an At-The-Market (ATM) offering raising $213,750 net during the quarter.
- Lease Liability: A new lease renewal in Cambridge, England, resulted in a significant increase in operating lease right-of-use assets ($1.79 million) and corresponding liabilities.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With cash of $1.66 million and a working capital deficit, the company anticipates needing to raise additional funds within the next 12 months to fund operations.
- Regulatory Status: The FDA 510(k) clearance for the IFP System (codeine) is now anticipated in the second half of calendar year 2026, following a request for additional information requiring a resubmission.
- Strategic Developments: Secured a major contract with a London public transport operator and a global distribution agreement with SMARTOX for the SmarTest Patch.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective due to material weaknesses in the control environment, risk assessment, and limited accounting personnel. Remediation plans include implementing new accounting systems and hiring additional staff.
- Risk Factors: Risks include potential delisting from Nasdaq due to stock price below $1.00, delays in FDA approval due to government shutdowns, and the inability to repay a $2.17 million grant to the Australian Government.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and certainty of upcoming capital raises given the explicit "substantial doubt" regarding going concern status.
- FDA Timeline: Confirm the specific requirements for the resubmitted 510(k) application and the feasibility of the H2 2026 clearance target.
- Grant Repayment: Assess the company's ability to repay the $2.17 million Australian Government grant obligation without further dilution or asset sales.
- Internal Controls: Monitor progress on remediation of material weaknesses in internal controls over financial reporting.
- Stock Price: Track compliance with Nasdaq minimum bid price requirements ($1.00) to avoid delisting risks.